Please use this identifier to cite or link to this item: http://sgc.anlis.gob.ar/handle/123456789/1422
Title: Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates
Authors: Quebrada Palacio, Luz P 
Gonzalez, Mariela N. 
Hernandez-Vasquez, Yolanda 
Perrone, Alina E. 
Parodi-Talice, Adriana 
Bua, Jacqueline 
Postan, Miriam 
Keywords: Variación Biológica Poblacional;Pruebas de Sensibilidad Microbiana;Trypanosoma cruzi
Issue Date: 5-Sep-2018
Journal: PloS one 
Abstract: 
Trypanosoma cruzi is a genetically heterogeneous group of organisms that cause Chagas disease. It has been long suspected that the clinical outcome of the disease and response to therapeutic agents are, at least in part, related to the genetic characteristics of the parasite. Herein, we sought to validate the significance of the genotype of T. cruzi isolates recovered from patients with different clinical forms of Chagas disease living in Argentina on their biological behaviour and susceptibility to drugs. Genotype identification of the newly established isolates confirmed the reported predominance of TcV, with a minor frequency of TcI. Epimastigote sensitivity assays demonstrated marked dissimilar responses to benznidazole, nifurtimox, pentamidine and dihydroartemisinin in vitro. Two TcV isolates exhibiting divergent response to benznidazole in epimastigote assays were further tested for the expression of anti-oxidant proteins. Benznidazole-resistant BOL-FC10A epimastigotes had decreased expression of Old Yellow Enzyme and cytosolic superoxide dismutase, and overexpression of mitochondrial superoxide dismutase and tryparedoxin- 1, compared to benznidazole-susceptible AR-SE23C parasites. Drug sensitivity assays on intracellular amastigotes and trypomastigotes reproduced the higher susceptibility of AR-SE23C over BOL-FC10A parasites to benznidazole observed in epimastigotes assays. However, the susceptibility/resistance profile of amastigotes and trypomastigotes to nifurtimox, pentamidine and dihydroartemisinin varied markedly with respect to that of epimastigotes. C3H/He mice infected with AR-SE23C trypomastigotes had higher levels of parasitemia and mortality rate during the acute phase of infection compared to mice infected with BOL-FC10A trypomastigotes. Treatment of infected mice with benznidazole or nifurtimox was efficient to reduce patent parasitemia induced by either isolate. Nevertheless, qPCR performed at 70 dpi revealed parasite DNA in the blood of mice infected with AR-SE23C but not in BOL-FC10A infected mice. These results demonstrate high level of intra-type diversity which may represent an important obstacle for the testing of chemotherapeutic agents.
Description: 
Fil: Quebrada Palacio, Luz P. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Argentina.

Fil: Gonzalez, Mariela N. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología. Departamento de Investigación y Docencia; Argentina.

Fil: Hernandez-Vasquez, Yolanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología. Departamento de Investigación y Docencia; Argentina.

Fil: Perrone, Alina E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología. Departamento de Investigación y Docencia; Argentina.

Fil: Parodi-Talice, Adriana. Universidad de la República. Facultad de Ciencias. Sección Genética. Instituto Pasteur de Montevideo. Unidad de Biología Molecular Montevideo; Uruguay.

Fil: Bua, Jacqueline. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Argentina.

Fil: Postan, Miriam. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Argentina.
URI: http://sgc.anlis.gob.ar/handle/123456789/1422
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0203462
Rights: Open Access
Creative Commons Attribution 4.0 International License
Appears in Collections:Publicaciones INP

Files in This Item:
File Description SizeFormat
PLoSOne_2018_13_9_e0203462.pdf7.41 MBAdobe PDFView/Open
Show full item record

Page view(s)

55
checked on Mar 28, 2024

Download(s)

3
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons